EA200500163A1 - Применение ингибиторов аланиламинопептидаз и содержащие их фармацевтические композиции - Google Patents

Применение ингибиторов аланиламинопептидаз и содержащие их фармацевтические композиции

Info

Publication number
EA200500163A1
EA200500163A1 EA200500163A EA200500163A EA200500163A1 EA 200500163 A1 EA200500163 A1 EA 200500163A1 EA 200500163 A EA200500163 A EA 200500163A EA 200500163 A EA200500163 A EA 200500163A EA 200500163 A1 EA200500163 A1 EA 200500163A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inhibitors
alynylaminopeptidases
application
pharmaceutical compositions
compositions containing
Prior art date
Application number
EA200500163A
Other languages
English (en)
Other versions
EA008946B1 (ru
Inventor
Зигфрид Анзорге
Янине Тадье
Уве Лендеккель
Original Assignee
Институт Фюр Медицинтехнологи Магдебург (Имтм) Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Институт Фюр Медицинтехнологи Магдебург (Имтм) Гмбх filed Critical Институт Фюр Медицинтехнологи Магдебург (Имтм) Гмбх
Publication of EA200500163A1 publication Critical patent/EA200500163A1/ru
Publication of EA008946B1 publication Critical patent/EA008946B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Изобретение относится к применению одного ингибитора или нескольких ингибиторов аланиламинопептидаз и/или ферментов такой же субстратной специфичности для индукции продуцирования TGF-β1 и экспрессии TGF-β1 в и/или на Treg-клетках и применению для профилактики и/или лечения аутоиммунных заболеваний, аллергий, артериосклероза и для подавления отторжений трансплантатов. Кроме того, изобретение относится к применениям, при которых используют дополнительно пептидные фрагменты патогенных аутоантигенов или синтетические аналоги и/или специфические антигенные компоненты патогенных микроорганизмов.Отчет о международном поиске был опубликован 2004.05.06.
EA200500163A 2002-07-05 2003-07-04 Применение ингибиторов аланиламинопептидаз и содержащие их фармацевтические композиции EA008946B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10230381A DE10230381A1 (de) 2002-07-05 2002-07-05 Verwendung von Inhibitoren der Alanyl-Aminopeptidasen und diese umfassende pharmazeutischen Zubereitungen
PCT/EP2003/007199 WO2004004750A2 (de) 2002-07-05 2003-07-04 Verwendung von inhibitoren der alanyl-aminopeptidasen und diese umfassende pharmazeutischen zubereitungen

Publications (2)

Publication Number Publication Date
EA200500163A1 true EA200500163A1 (ru) 2005-08-25
EA008946B1 EA008946B1 (ru) 2007-10-26

Family

ID=29761689

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200500163A EA008946B1 (ru) 2002-07-05 2003-07-04 Применение ингибиторов аланиламинопептидаз и содержащие их фармацевтические композиции

Country Status (9)

Country Link
US (1) US7425532B2 (ru)
EP (2) EP2085094A2 (ru)
JP (1) JP2005532380A (ru)
CN (1) CN1665524B (ru)
AU (1) AU2003250892B2 (ru)
CA (1) CA2490714A1 (ru)
DE (1) DE10230381A1 (ru)
EA (1) EA008946B1 (ru)
WO (1) WO2004004750A2 (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10348022A1 (de) * 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
DE10348023A1 (de) * 2003-10-15 2005-05-19 Imtm Gmbh Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
DE10348044A1 (de) 2003-10-15 2005-05-19 Imtm Gmbh Duale Alanyl-Aminopeptidase- und Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
US20060063208A1 (en) 2004-08-02 2006-03-23 Woolf Clifford J DRG11-responsive (DRAGON) gene and uses thereof
EP1669086A1 (en) * 2004-12-09 2006-06-14 Advitech Solutions Inc. Composition comprising TGF-beta and proteins for treating psoriasis
US7763257B2 (en) 2004-12-09 2010-07-27 Christina Juneau Compositions comprising transforming growth factor (TGF)-β1 and TGF-β2 in admixture of proteins obtained from dairy products
EP2954903A1 (en) 2005-02-16 2015-12-16 The General Hospital Corporation Use of bmp antagonists to regulate hepcidin-mediated iron metabolism
US9604931B2 (en) * 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US9623021B2 (en) * 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
EA019833B1 (ru) 2007-01-22 2014-06-30 ДЖиТиЭкс, ИНК. Вещества, связывающие ядерные рецепторы
ES2308916B1 (es) * 2007-03-22 2009-10-29 Consejo Superior De Investigaciones Cientificas Compuesto inhibidor dual de las enzimas pde7 y/o pde4, composiciones farmaceuticas y sus aplicaciones.
WO2008124768A1 (en) 2007-04-09 2008-10-16 The General Hospital Corporation Hemojuvelin fusion proteins and uses thereof
DE102007039429A1 (de) * 2007-08-21 2009-02-26 Imtm Gmbh Verfahren zur Aktivierung regulatorischer T-Zellen
CN104922669A (zh) 2008-11-13 2015-09-23 通用医疗公司 用于通过调整bmp-6来调节铁稳态的方法和组合物
EP2366394A1 (en) 2010-03-17 2011-09-21 IMTM GmbH Characterization and validation of inhibitors and ligands of dipeptidyl aminopeptidase IV (DP IV)
CN102631664B (zh) * 2011-01-28 2014-10-01 上海来益生物药物研究开发中心有限责任公司 3-氨基-2-羟基-4-苯基-缬氨酰-异亮氨酸的应用
US9783616B2 (en) * 2013-04-02 2017-10-10 University Of Connecticut Regulating transplant rejection of donor and embryonic stem cell-derived tissues and organs
US20200325239A1 (en) * 2016-06-10 2020-10-15 The Regents Of The University Of Michigan Modulation of Aminopeptidase N/CD13 and Rheumatoid Arthritis

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3347531A1 (de) * 1983-12-30 1985-07-11 Basf Ag, 6700 Ludwigshafen Magnetische aufzeichnungstraeger
EP0189569B1 (de) * 1984-12-22 1989-02-01 EJOT Adolf Böhl GmbH & Co. KG Befestigungselement
WO1991008760A1 (en) 1989-12-20 1991-06-27 Brigham And Women's Hospital Improved treatment of autoimmune diseases by aerosol administration of auto antigens
AU7376494A (en) * 1993-08-04 1995-02-28 Andrulis Pharmaceuticals Corporation Treatment of rheumatoid arthritis with thalidomide alone or in combination with other anti-inflammatory agents
EP0787147A1 (en) 1994-10-25 1997-08-06 Immulogic Pharmaceutical Corporation Compositions and treatment for multiple sclerosis
JP3917711B2 (ja) * 1997-05-12 2007-05-23 財団法人微生物化学研究会 フェベスチン誘導体
JP2001131066A (ja) * 1999-08-25 2001-05-15 Nippon Kayaku Co Ltd アポトーシス増強剤
JP2001089360A (ja) * 1999-09-16 2001-04-03 Shionogi & Co Ltd Ｔリンパ球増殖反応の低下剤
DE10002820A1 (de) 2000-01-24 2001-08-23 Walter Schubert Aminopeptidasen-Inhibitor
DE10025464A1 (de) 2000-05-23 2001-12-06 Inst Medizintechnologie Magdeb Kombinierte Verwendung von Enzyminhibitoren zur Therapie von Autoimmunerkrankungen, bei Transplantationen und Tumorerkrankungen sowie Kombinationen von Enzyminhibitoren umfassende pharmazeutische Zubereitungen
DE10100052A1 (de) * 2001-01-02 2002-07-11 Inst Medizintechnologie Magdeb Kombinierte Verwendung von Enzyminhibitoren und pharmazeutischen Zubereitungen daraus zur Therapie und Prophylaxe der Atheriosklerose
DE10211555A1 (de) * 2002-03-15 2003-10-02 Imtm Inst Fuer Medizintechnolo Verwendung der Inhibitoren von Enzymen mit Aktivitäten der Aminopeptidase N und/oder der Dipeptidylpeptidase IV und pharmazeutischen Zubereitungen daraus zur Therapie und Prävention dermatologischer Erkrankungen mit sebozytärer Hyperproliferation und veränderten Differenzierungszuständen

Also Published As

Publication number Publication date
EP2085094A2 (de) 2009-08-05
CN1665524B (zh) 2010-08-25
DE10230381A1 (de) 2004-01-22
EP1521588A2 (de) 2005-04-13
WO2004004750A2 (de) 2004-01-15
AU2003250892B2 (en) 2006-11-16
US20060211602A1 (en) 2006-09-21
EA008946B1 (ru) 2007-10-26
CA2490714A1 (en) 2004-01-15
WO2004004750A3 (de) 2004-05-06
AU2003250892A1 (en) 2004-01-23
US7425532B2 (en) 2008-09-16
CN1665524A (zh) 2005-09-07
JP2005532380A (ja) 2005-10-27

Similar Documents

Publication Publication Date Title
EA200500163A1 (ru) Применение ингибиторов аланиламинопептидаз и содержащие их фармацевтические композиции
ATE267830T1 (de) Als cox-hemmer verwendbare sulfonylphenylpyrazol- verbindungen
DE60330485D1 (de) Zur behandlung von diabetes
BG66084B1 (bg) Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
DE69410092T2 (de) Phenyl heterocyclen als cyclooxygenase-2 inhibitoren
DK1480961T3 (da) Glutaminylbaserede DPIV-inhibitorer
DE60329316D1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
DE602004019548D1 (de) Kondensierte heterocyclen als inhibitoren von glutamatracemase (muri)
EA200800375A1 (ru) Соединения и способы ингибирования экспрессии vcam-1
EA200300441A1 (ru) Ассоциация антагониста рецептора св1 и сибутрамина, содержащие их фармацевтические композиции и их применение для лечения ожирения
WO2004047728A3 (en) Compositions and methods for the treatment of immune related diseases
WO2004039956A3 (en) Compositions and methods for the treatment of immune related diseases
MEP90508A (en) New pharmaceutical composition
DE60118723D1 (de) Verwendung von azetogenischen hydrogenotrophischen stämmen zur vorbeugung und behandlung von verdauungskrankheiten
DE60122767D1 (de) Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
DE69905476D1 (en) Phosphonsaürederivate als ptp-1b-inhibitoren
DE69837324D1 (de) Behandlung der multiplen sklerose durch einnahme von copolymer-1
DE60323765D1 (de) Inhibitoren der 17 beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten
ATE414526T1 (de) Zubereitungen zur behandlung von arthritischen erscheinungen
YU79202A (sh) Peptid koji modulira trombopoetinski receptor
FR2861731B1 (fr) Nouvelle proteine de fixation du phosphate, compositions pharmaceutiques la contenant et ses utilisations
DE60035693D1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
DE69614824T2 (de) Verfahren zur herstellung von retrovial protease hemmenden zwischenprodukten
WO2004024072A3 (en) Novel compositions and methods for the treatment of immune related diseases
DE69513837T2 (de) Cyklopeptolide

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU